Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15441837 | 0.95 | ALDH1A1 (0.54) | ALDH1A1KDM4ETNK2MEN1KMT2A | |
| SCHEMBL7929464 | 0.95 | ALDH1A1 (0.60) | ALDH1A1KDM4ETNK2MEN1KMT2A | |
| SCHEMBL3500438 | 0.86 | TNK2 (0.44) | ALDH1A1KDM4ETNK2MEN1KMT2A | |
| SCHEMBL7285052 | 0.85 | ALDH1A1 (0.42) | ALDH1A1KDM4ETNK2MEN1KMT2A | |
| SCHEMBL7285049 | 0.85 | ALDH1A1 (0.42) | ALDH1A1KDM4ETNK2MEN1KMT2A | |
| SCHEMBL9876349 | 0.84 | KDM4E (0.39) | ALDH1A1KDM4ETNK2MEN1KMT2A | |
| SCHEMBL412542 | 0.84 | ALDH1A1 (0.39) | ALDH1A1KDM4ETNK2MEN1KMT2A | |
| SCHEMBL3394710 | 0.83 | MEN1 (0.42) | ALDH1A1KDM4ETNK2MEN1KMT2A | |
| SCHEMBL2204157 | 0.82 | DHFR (0.46) | ALDH1A1KDM4EMEN1KMT2ADHFR | |
| SCHEMBL29646493 | 0.82 | DHFR (0.46) | ALDH1A1KDM4EMEN1KMT2ADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1568690-A1 | The use of carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones as sodium channel blockers | Euro-Celtique S.A. (LU) | 2005-08-31 | — | — | EP | claimed |
| US-20050089793-A1 | Compound having an epoxy group and a chalcone group, method of preparing the same, and photoresist composition comprising the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2005-04-28 | — | — | US | claimed |
| EP-0986540-B1 | THE USE OF CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AS SODIUM CHANNEL BLOCKERS | EURO CELTIQUE SA (LU) | 2005-02-16 | — | — | EP | claimed |
| US-6696442-B2 | THERAPY OF DISORDER RESPONSIVE TO THE BLOCKADE OF SODIUM CHANNELS IN A MAMMAL SUFFERING THEREFROM BY ADMINISTERING CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES, WHICH ACT AS BLOCKERS OF SODIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2004-02-24 | — | — | US | claimed |
| US-20030225080-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | EURO-CELTIQUES S.A. | 2003-12-04 | — | — | US | claimed |
| US-6638947-B2 | Blockers of sodium channels; treatment of neuronal damage following global and focal ischemia, treatment or prevention of neurodegenerative conditions, pain | EURO-CELTIQUE S.A. (LU) | 2003-10-28 | — | — | US | claimed |
| US-6613803-B1 | Treating, preventing or ameliorating pain | EURO-CELTIQUE S.A. (LU) | 2003-09-02 | — | — | US | claimed |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-12-05 | — | — | US | claimed |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-05-23 | — | — | US | claimed |
| JP-2001526648-A | — | — | 2001-12-18 | — | — | JP | claimed |
| EP-0986540-A4 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS INC (US) | 2001-07-11 | — | — | EP | claimed |
| EP-0986540-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | Cocensys, Inc. (US) | 2000-03-22 | — | — | EP | claimed |
| WO-1998047869-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS, INC. (US) | 1998-10-29 | — | — | WO | claimed |
| US-20260093178-A1 | POLYMER, METHOD OF PRODUCING THE SAME, RESIST COMPOSITION INCLUDING THE POLYMER, AND PATTERN FORMATION METHOD USING THE RESIST COMPOSITION | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2026-04-02 | — | — | US | disclosed |
| CN-119677514-A | Estrogenic compounds and methods of use | 益特瑞恩公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-114867731-B | Dendrimers and derivatives thereof having a thiophosphamide crystal structure | 国家科学研究中心 | 2024-08-16 | — | — | CN | disclosed |
| EP-0005889-B1 | PROCESS FOR THE PREPARATION OF BETA-LACTAM DERIVATIVES, THE NOVEL DERIVATIVES SO OBTAINABLE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Technobiotic Ltd. (CH) | 1982-06-16 | — | — | EP | disclosed |
| US-4283531-A | Synthesis of β-lactams having a substituted hydroxymethylene group at the position α to the lactam carbonyl group | SCHERING CORPORATION (US) | 1981-08-11 | — | — | US | disclosed |
| US-4272439-A | 6-(Substituted-hydroxymethylene penams) | SCHERING CORPORATION (US) | 1981-06-09 | — | — | US | disclosed |
| EP-0005889-A1 | Process for the preparation of beta-lactam derivatives, the novel derivatives so obtainable and pharmaceutical compositions containing them | Technobiotic Ltd. (CH) | 1979-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225080-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, SLC1A1, SOD1 | ALDH1A1 91/4885KDM4E 3771/4885TNK2 4798/4885 |
| US-20260093178-A1 | POLYMER, METHOD OF PRODUCING THE SAME, RESIST COMPOSITION INCLUDING THE POLYMER, AND PATTERN FORMATION METHOD USING THE RESIST COMPOSITION | RPS21, CA11, RPL21 | ALDH1A1 1875/4885KDM4E 3844/4885TNK2 3637/4885 |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, SLC1A1, SOD1 | ALDH1A1 91/4885KDM4E 3771/4885TNK2 4798/4885 |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, CBR1, ALDH1A2 | ALDH1A1 97/4885KDM4E 3849/4885TNK2 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.